Ixazomib administration for 13 months in an 81-year-old man with multiple myeloma caused a decline in left ventricular ejection fraction from 53% to 35% and development of irreversible heart failure despite discontinuation and guideline-directed therapy.
Case Report (n=1)
No
Ixazomib can cause severe and irreversible cancer therapy-related cardiac dysfunction, emphasizing the need for baseline cardiovascular risk stratification and monitoring in elderly patients.
Absolute Event Rate: 35% vs 53%
An 81-year-old man with a history of multiple myeloma presented with decompensated heart failure (HF). Although his baseline left ventricular ejection fraction (LVEF) was preserved, it significantly declined to 35% at 13 months after the initiation of ixazomib. Considering the chronological relationship between the timing of ixazomib treatment and symptom onset, prior normal echocardiography, and multimodal imaging findings, ixazomib-induced cancer therapy-related cardiac dysfunction (CTRCD) was strongly suspected. Despite the discontinuation of ixazomib and continued administration of guideline-directed medical therapy, his LVEF has not recovered to date. We herein report a rare case of ixazomib-induced irreversible CTRCD.
Hirao et al. (Thu,) conducted a case report in multiple myeloma with cancer therapy-related cardiac dysfunction (n=1). ixazomib was evaluated on Left ventricular ejection fraction (LVEF) decline and heart failure development. Ixazomib administration for 13 months in an 81-year-old man with multiple myeloma caused a decline in left ventricular ejection fraction from 53% to 35% and development of irreversible heart failure despite discontinuation and guideline-directed therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: